- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry2023 | First Faculty of Medicine, Third Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Etanercept - adherence to treatment, treatment retentiont; data from biologic registries2014 | Publication without faculty affiliation
- FRI0107 THE EFFECT OF CO-MEDICATION WITH METHOTREXATE OR OTHER CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON FIRST TUMOR NECROSIS INHIBITOR DRUG SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CZECH ATTRA REGISTRYPublication without faculty affiliation
- Evaluation of consequences of occupational exposure to carcinogens in various branches of industry2009 | Second Faculty of Medicine
- Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA2020 | First Faculty of Medicine
- Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries2018 | First Faculty of Medicine, Third Faculty of Medicine
- Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Gender difference in disease severity and treatment outcomes among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) starting treatment with targeted therapies in the Czech Republic - analysis from the nation-wide ATTRA registry of biological therapy2021 | First Faculty of Medicine
- Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry2022 | First Faculty of Medicine
- Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic2023 | First Faculty of Medicine, Third Faculty of Medicine